Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chugai Pharmaceutical CoTSE:4519 -2.15%96 Interest Coverage is No Debt (1) as of Mar. 2026, which is 100% below its 10-year median of 3,875.73. GuruFocus rates TSE:4519 with a GF Score™ of 96/100 and a GF Value™ of 円7,735.19 (Fairly Valued). The stock has 1 warning sign investors should review. Among 687 Drug Manufacturers companies, Chugai Pharmaceutical Co ranks worse than 145560.26% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Chugai Pharmaceutical Co's
Operating Income
for the
three
months ended in Mar. 2026 was 円158,765 Mil. Chugai Pharmaceutical Co's Interest Expense for the
three
months ended in Mar. 2026 was 円0 Mil.
Chugai Pharmaceutical Co has no debt.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Chugai Pharmaceutical Co Ltd has no debt.
(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
The historical rank and industry rank for Chugai Pharmaceutical Co's Interest Coverage or its related term are showing as below:
TSE:4519's Interest Coverage is not ranked *
in the Drug Manufacturers industry.
Industry Median: 12.75 * Ranked among companies with meaningful Interest Coverage only.
Chugai Pharmaceutical Co (TSE:4519) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Chugai Pharmaceutical Co Interest Coverage Related Terms
Chugai Pharmaceutical Co Interest Coverage Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
TSE:4519 vs LLY, JNJ, ABBV: Interest Coverage Comparison
For the Drug Manufacturers - General subindustry, Chugai Pharmaceutical Co's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chugai Pharmaceutical Co Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Chugai Pharmaceutical Co's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Chugai Pharmaceutical Co's Interest Coverage falls into.
Chugai Pharmaceutical Co Interest Coverage Calculation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Coverage of No Debt <sup>(1)</sup> mean?
Chugai Pharmaceutical Co (TSE:4519) has a Interest Coverage of No Debt (1) as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Chugai Pharmaceutical Co and its competitors. This is 100% below median its historical median of 3,875.73. Over the past decade, Chugai Pharmaceutical Co's Interest Coverage has ranged from 894.00 to 16,265.70. According to the industry distribution chart, Chugai Pharmaceutical Co ranks #999999 out of 687 companies in the Drug Manufacturers industry.
Is Chugai Pharmaceutical Co's Interest Coverage too high?
Chugai Pharmaceutical Co's current Interest Coverage of No Debt (1) is 100% below median its 10-year median of 3,875.73. Over the past 10 years, this metric has ranged from a low of 894.00 to a high of 16,265.70. Based on the distribution chart, Chugai Pharmaceutical Co ranks #999999 out of 687 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Chugai Pharmaceutical Co has a GF Score™ of 96/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Chugai Pharmaceutical Co's Interest Coverage compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Chugai Pharmaceutical Co ranks #999999 out of 687 companies for Interest Coverage. This places Chugai Pharmaceutical Co in the lower half of its industry. The industry median Interest Coverage is 12.75. Historically, Chugai Pharmaceutical Co's own Interest Coverage has ranged from 894.00 to 16,265.70 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.75, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Chugai Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chugai Pharmaceutical Co's current Interest Coverage is No Debt (1), which is 100% below median its own 10-year median of 3,875.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chugai Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Chugai Pharmaceutical Co (TSE:4519) is currently considered Fairly Valued. The stock's GF Value™ is 円7,735.19, compared to a current price of 円7,230.00 — trading 6.5% below its estimated fair value. The current Interest Coverage is No Debt (1), which is 100% below median its 10-year median of 3,875.73. Chugai Pharmaceutical Co's overall GF Score™ is 96/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Chugai Pharmaceutical Co (TSE:4519), the current Interest Coverage is No Debt (1) as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chugai Pharmaceutical Co (TSE:4519) Overvalued in 2026?
Based on GuruFocus' analysis, Chugai Pharmaceutical Co stock appears to be undervalued.
The current stock price of 円7,230.00 is trading 6.5% below its estimated GF Value™ of 円7,735.19.
GuruFocus considers Chugai Pharmaceutical Co to be Fairly Valued.
Key valuation signals for TSE:4519:
Interest Coverage: No Debt (1) (100% below median its 10-year median of 3,875.73)
GF Value™: 円7,735.19 vs. price of 円7,230.00 (6.5% below fair value)
No single metric tells the full story. See the TSE:4519 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra (hemophilia), Actemra (rheumatoid arthritis, covid), Foundayo (oral obesity pill), and Nemluvio (atopic dermatitis, prurigo nodularis).
96GF Score
Get the complete analysis for TSE:4519
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4519 has been successfully added to your 
